Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.
Also called NCT02648464
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 125 participants
- Registry
-
NCT02648464
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Finland
- Registry status
- Completed
Technical summary
Registry record NCT02648464. Randomized; triple masking; primary purpose treatment. Start 2016-02-01 (actual); primary completion 2019-12-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial
- Acronym
- OXI
- Condition
- Myocardial Infarction
- Condition
- Acute Coronary Syndrome
- Condition
- Inflammation
- Condition
- Hydroxychloroquine
- Condition
- Antirheumatic Agents
- Condition
- Cardiovascular Diseases
- Intervention (Drug)
- Hydroxychloroquine
- Intervention (Drug)
- Placebo
- Lead sponsor
- Helsinki University Central Hospital
- Collaborator
- Finnish Foundation for Cardiovascular Research
- Collaborator
- Orion Corporation, Orion Pharma
- Collaborator
- Aarne Koskelo Foundation
- Collaborator
- Finnish Cultural Foundation
Record details
- Record id
cardio:ct-nct02648464- Content hash
997f5c778ff38602658351a15f0b0fee024e38b4ee86ef28bf2f5e9bfeb911e3